Pharma R&D Today
Ideas and Insight supporting all stages of Drug Discovery & Development
Broadening the Field of Research While Staying Focused
Posted on June 7th, 2017 by Patrik Brehm in Pharma R&D
Since joining The Hive, our team at Myelo Therapeutics has had the opportunity to train on and utilize a number of Elsevier’s information solutions, and they have already made a significant impact on our work, whether using Scopus to find collaborators or analyzing chemical structures with Reaxys.
The latest of the tools that we’ve tried has been Pathway Studio, which helps researchers working in drug discovery to analyze relationships between biological molecules and processes.
As an initial reaction to Pathway Studio, we were overwhelmed by the sheer amount of content accessible – and, thus, the many research possibilities. Up to now, a major hurdle of delving deeper into certain research topics of interest was that linking papers was not easily possible, especially when multiple topics come together. As such, Pathway Studio allows immense flexibility and provides heaps of data to delve into. While we could have been in danger of getting lost in connections between proteins of interest, their molecular partners and further downstream targets, Pathway Studio’s extensive filtering options allowed us to retain focus and therefore broaden our exploratory research without losing the important connections to the starting point.
My personal initial impression is that Pathway Studio will be my major go-to software in finding papers of interest over the following months.
Find out more about Pathway Studio.
All opinions shared in this post are the author’s own.
R&D Solutions for Pharma & Life SciencesWe're happy to discuss your needs and show you how Elsevier's Solution can help.
Preclinical Research Manager at Myelo Therapeutics
- The Power of Two in Lead Optimization
- Leveling the Playing Field in Medicinal Chemistry
- The Hive is open for 2017 applicants
- Predicting Adverse Event Risks and Gaining Insights from Disparate Data
- Avoiding the Risks of Being Wrong in Drug Discovery